BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26147452)

  • 21. Epstein-Barr virus, rapamycin, and host immune responses.
    Krams SM; Martinez OM
    Curr Opin Organ Transplant; 2008 Dec; 13(6):563-8. PubMed ID: 19060543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular epidemiology of EBNA-1 substrains of Epstein-Barr virus in posttransplant lymphoproliferative disorders which have infrequent p53 mutations.
    Greiner TC; Abou-Elella AA; Smir BN; Orazi A; Hinrichs S; Anderson J; Gross T; Bierman P; Hauke R
    Leuk Lymphoma; 2000 Aug; 38(5-6):563-76. PubMed ID: 10953978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The biology of Epstein-Barr virus in post-transplant lymphoproliferative disease.
    Hsieh WS; Lemas MV; Ambinder RF
    Transpl Infect Dis; 1999 Sep; 1(3):204-12. PubMed ID: 11428990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.
    Hart M; Thakral B; Yohe S; Balfour HH; Singh C; Spears M; McKenna RW
    Am J Surg Pathol; 2014 Nov; 38(11):1522-9. PubMed ID: 25007145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The viral and cellular microRNA targetome in lymphoblastoid cell lines.
    Skalsky RL; Corcoran DL; Gottwein E; Frank CL; Kang D; Hafner M; Nusbaum JD; Feederle R; Delecluse HJ; Luftig MA; Tuschl T; Ohler U; Cullen BR
    PLoS Pathog; 2012 Jan; 8(1):e1002484. PubMed ID: 22291592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-transplant lymphoproliferative disorders and Epstein-Barr virus DNAemia in a cohort of lung transplant recipients.
    Baldanti F; Rognoni V; Cascina A; Oggionni T; Tinelli C; Meloni F
    Virol J; 2011 Sep; 8():421. PubMed ID: 21892950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. B-cell posttransplant lymphoproliferative disorder isolated to the central nervous system is Epstein-Barr virus positive and lacks p53 and Myc expression by immunohistochemistry.
    Sundin A; Grzywacz BJ; Yohe S; Linden MA; Courville EL
    Hum Pathol; 2017 Mar; 61():140-147. PubMed ID: 27993575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epstein-Barr virus (EBV)-positive lymphoproliferations in post-transplant patients show immunoglobulin V gene mutation patterns suggesting interference of EBV with normal B cell differentiation processes.
    Bräuninger A; Spieker T; Mottok A; Baur AS; Küppers R; Hansmann ML
    Eur J Immunol; 2003 Jun; 33(6):1593-602. PubMed ID: 12778477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epstein-Barr virus (EBV) genotypes among human immunodeficiency virus (HIV)-related B-cell lymphomas and B-cell post-transplant lymphoproliferative disorders (B-PTLD)--late-onset lymphomas, especially in the HIV setting, are associated with type-B-EBV.
    Ibrahim HA; Menasce LP; Pomplun S; Burke M; Bower M; Naresh KN
    Eur J Haematol; 2010 Sep; 85(3):227-30. PubMed ID: 20408873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD.
    Sebelin-Wulf K; Nguyen TD; Oertel S; Papp-Vary M; Trappe RU; Schulzki A; Pezzutto A; Riess H; Subklewe M
    Transpl Immunol; 2007 Apr; 17(3):203-10. PubMed ID: 17331848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An Epstein-Barr Virus MicroRNA Blocks Interleukin-1 (IL-1) Signaling by Targeting IL-1 Receptor 1.
    Skinner CM; Ivanov NS; Barr SA; Chen Y; Skalsky RL
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28794034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early gene expression changes by Epstein-Barr virus infection of B-cells indicate CDKs and survivin as therapeutic targets for post-transplant lymphoproliferative diseases.
    Bernasconi M; Ueda S; Krukowski P; Bornhauser BC; Ladell K; Dorner M; Sigrist JA; Campidelli C; Aslandogmus R; Alessi D; Berger C; Pileri SA; Speck RF; Nadal D
    Int J Cancer; 2013 Nov; 133(10):2341-50. PubMed ID: 23640782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
    Oertel S; Trappe RU; Zeidler K; Babel N; Reinke P; Hummel M; Jonas S; Papp-Vary M; Subklewe M; Dörken B; Riess H; Gärtner B
    Ann Hematol; 2006 Jul; 85(7):478-84. PubMed ID: 16586109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interactions involving cyclosporine A, interleukin-6, and Epstein-Barr virus lead to the promotion of B-cell lymphoproliferative disease.
    Tanner JE; Alfieri C
    Leuk Lymphoma; 1996 May; 21(5-6):379-90. PubMed ID: 9172802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry.
    Zimmermann H; Oschlies I; Fink S; Pott C; Neumayer HH; Lehmkuhl H; Hauser IA; Dreyling M; Kneba M; Gärtner B; Anagnostopoulos I; Riess H; Klapper W; Trappe RU
    Transplantation; 2012 Mar; 93(5):543-50. PubMed ID: 22234349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Posttransplant lymphoproliferative disorder associated with an Epstein-Barr-related virus in cynomolgus monkeys.
    Schmidtko J; Wang R; Wu CL; Mauiyyedi S; Harris NL; Della Pelle P; Brousaides N; Zagachin L; Ferry JA; Wang F; Kawai T; Sachs DH; Cosimi BA; Colvin RB
    Transplantation; 2002 May; 73(9):1431-9. PubMed ID: 12023621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adapted treatment of Epstein-Barr virus infection to prevent posttransplant lymphoproliferative disorder after heart transplantation.
    Choquet S; Varnous S; Deback C; Golmard JL; Leblond V
    Am J Transplant; 2014 Apr; 14(4):857-66. PubMed ID: 24666832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice.
    Caduff N; McHugh D; Murer A; Rämer P; Raykova A; Landtwing V; Rieble L; Keller CW; Prummer M; Hoffmann L; Lam JKP; Chiang AKS; Raulf F; Azzi T; Berger C; Rubic-Schneider T; Traggiai E; Lünemann JD; Kammüller M; Münz C
    PLoS Pathog; 2020 Apr; 16(4):e1008477. PubMed ID: 32251475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.